🎉 M&A multiples are live!
Check it out!

Immunome Valuation Multiples

Discover revenue and EBITDA valuation multiples for Immunome and similar public comparables like Pharming, Benevolent AI, and Vivoryon Therapeutics.

Immunome Overview

About Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.


Founded

2006

HQ

United States of America
Employees

118

Website

immunome.com

Financials

LTM Revenue $7.0M

LTM EBITDA -$296M

EV

$427M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Immunome Financials

Immunome has a last 12-month revenue of $7.0M and a last 12-month EBITDA of -$296M.

In the most recent fiscal year, Immunome achieved revenue of $9.0M and an EBITDA of -$151M.

Immunome expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Immunome valuation multiples based on analyst estimates

Immunome P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $14.0M $9.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$28.0M -$151M XXX XXX XXX
EBITDA Margin -200% -1674% XXX XXX XXX
Net Profit -$36.9M -$107M XXX XXX XXX
Net Margin -263% -1181% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Immunome Stock Performance

As of April 15, 2025, Immunome's stock price is $7.

Immunome has current market cap of $639M, and EV of $427M.

See Immunome trading valuation data

Immunome Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$427M $639M XXX XXX XXX XXX $-4.31

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Immunome Valuation Multiples

As of April 15, 2025, Immunome has market cap of $639M and EV of $427M.

Immunome's trades at 61.0x LTM EV/Revenue multiple, and -1.4x LTM EBITDA.

Analysts estimate Immunome's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Immunome and 10K+ public comps

Immunome Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $427M XXX XXX XXX
EV/Revenue 47.2x XXX XXX XXX
EV/EBITDA -2.8x XXX XXX XXX
P/E -2.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Immunome Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Immunome Valuation Multiples

Immunome's NTM/LTM revenue growth is -17%

Immunome's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Immunome's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Immunome's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Immunome and other 10K+ public comps

Immunome Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -36% XXX XXX XXX XXX
EBITDA Margin -1674% XXX XXX XXX XXX
EBITDA Growth 441% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -1692% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 365% XXX XXX XXX XXX
R&D Expenses to Revenue 1433% XXX XXX XXX XXX
Opex to Revenue 1797% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Immunome Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Immunome M&A and Investment Activity

Immunome acquired  XXX companies to date.

Last acquisition by Immunome was  XXXXXXXX, XXXXX XXXXX XXXXXX . Immunome acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Immunome

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Immunome

When was Immunome founded? Immunome was founded in 2006.
Where is Immunome headquartered? Immunome is headquartered in United States of America.
How many employees does Immunome have? As of today, Immunome has 118 employees.
Who is the CEO of Immunome? Immunome's CEO is Dr. Clay B. Siegall,PhD.
Is Immunome publicy listed? Yes, Immunome is a public company listed on NAS.
What is the stock symbol of Immunome? Immunome trades under IMNM ticker.
When did Immunome go public? Immunome went public in 2020.
Who are competitors of Immunome? Similar companies to Immunome include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Immunome? Immunome's current market cap is $639M
What is the current revenue of Immunome? Immunome's last 12-month revenue is $7.0M.
What is the current EBITDA of Immunome? Immunome's last 12-month EBITDA is -$296M.
What is the current EV/Revenue multiple of Immunome? Current revenue multiple of Immunome is 61.0x.
What is the current EV/EBITDA multiple of Immunome? Current EBITDA multiple of Immunome is -1.4x.
What is the current revenue growth of Immunome? Immunome revenue growth between 2023 and 2024 was -36%.
Is Immunome profitable? Yes, Immunome is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.